Biosidus Expands Biological Drug Production and Global Supply Capabilities
Argentinian biotech firm Biosidus has launched a new facility equipped with bioreactors, increasing its capacity for biological drug manufacturing and enhancing global supply capabilities.
Argentinian biotechnology firm Biosidus has significantly expanded its production capacity with the launch of a new facility in Buenos Aires. The new plant is equipped with modern bioreactors, enabling an increase in the manufacturing of biological drugs, such as beta-agalzidasi.
The expansion aims to meet growing global demand and improve the company's ability to supply medicines to international markets. Biosidus, with over four decades of experience in developing and manufacturing biosimilars, seeks to strengthen its position in the biotechnology sector.
The new facility is part of the company's strategy to streamline production processes and ensure the availability of high-quality pharmaceuticals. Enhancing the supply chain is critical to guaranteeing efficient and reliable distribution of these medicines to patients worldwide.
Biosidus has a history of developing and manufacturing various biological drugs. The increased production capabilities support the company's goals of broadening its product portfolio and serving a wider patient population.